These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38442705)

  • 1. Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment.
    Fukushima T; Kobatake K; Miura K; Takemoto K; Yamanaka R; Tasaka R; Kohada Y; Miyamoto S; Sekino Y; Kitano H; Goto K; Ikeda K; Goriki A; Hieda K; Kaminuma O; Hinata N
    Oncology; 2024 Mar; ():. PubMed ID: 38442705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients.
    Li P; Xiao J; Zhou B; Wei J; Luo J; Chen W
    Aging (Albany NY); 2020 Oct; 12(19):19316-19324. PubMed ID: 33031058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The KASH-containing isoform of Nesprin1 giant associates with ciliary rootlets of ependymal cells.
    Potter C; Razafsky D; Wozniak D; Casey M; Penrose S; Ge X; Mahjoub MR; Hodzic D
    Neurobiol Dis; 2018 Jul; 115():82-91. PubMed ID: 29630990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Isoforms of Nesprin1 Are Integral Components of Ciliary Rootlets.
    Potter C; Zhu W; Razafsky D; Ruzycki P; Kolesnikov AV; Doggett T; Kefalov VJ; Betleja E; Mahjoub MR; Hodzic D
    Curr Biol; 2017 Jul; 27(13):2014-2022.e6. PubMed ID: 28625779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
    Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
    Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer.
    Elgendy M; Fusco JP; Segura V; Lozano MD; Minucci S; Echeveste JI; Gurpide A; Andueza M; Melero I; Sanmamed MF; Ruiz MR; Calvo A; Pascual JI; Velis JM; Miñana B; Valle RD; Pio R; Agorreta J; Abengozar M; Colecchia M; Brich S; Renne SL; Guruceaga E; Patiño-García A; Perez-Gracia JL
    Int J Cancer; 2019 Oct; 145(7):1991-2001. PubMed ID: 30848481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Wei Y; Chen X; Ren X; Wang B; Zhang Q; Bu H; Qian J; Shao P
    Front Genet; 2021; 12():680369. PubMed ID: 34306023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
    BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma.
    Chen Z; Li Z; Li C; Li B; Wang H; Nong D; Li X; Huang G; Lin J; Li W
    BMC Cancer; 2022 Dec; 22(1):1277. PubMed ID: 36474188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma.
    Lin J; Tang Z; Zhang C; Dong W; Liu Y; Huang H; Liu H; Huang J; Lin T; Chen X
    Heliyon; 2023 May; 9(5):e16076. PubMed ID: 37215783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma.
    Kobatake K; Ikeda K; Teishima J; Sekino Y; Babasaki T; Kohada Y; Tasaka R; Takemoto K; Fukushima T; Miyamoto S; Kitano H; Goto K; Hieda K; Hayashi T; Hinata N
    Front Oncol; 2022; 12():1039383. PubMed ID: 36568232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment.
    Bouchalova P; Beranek J; Lapcik P; Potesil D; Podhorec J; Poprach A; Bouchal P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome.
    Sato M; Nakai Y; Nakata W; Yoshida T; Hatano K; Kawashima A; Fujita K; Uemura M; Takayama H; Nonomura N
    PLoS One; 2013; 8(9):e74313. PubMed ID: 24073208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.